Biogenes technologies
Latest round
- Series A
Last raised
- Jan 2023
Total raised
- $5.7M
Investors
- 1
About Biogenes technologies
Based in Selangor, Malaysia, and founded in 2015, Biogenes Technologies Sdn.a. Biogenes Technologies is a biotech company that develops, produces, and markets synthetic antibody diagnostics products through its proprietary platform for molecular diagnostics applications. In January 2023, Biogenes Technologies Sdn. Bhd. Biogenes Technologies develops aptamer-based diagnostics products from molecular diagnostics and genomics for a wide range of applications, such as human healthcare, animal health, agriculture, food safety, and environmental monitoring. The company also provides platform technologies that include printed nano-coated sensors, aptamers (synthetic antibodies), immobilization of DNA probes, validation of new aptamers, and in-silico design. In addition, the firm offers a mobile application that allows complete control of the APTSENS reader.
Who invested in Biogenes technologies
1 investor across 1 round
See all investors in Biogenes technologies
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jan 18, 2023
Amount
$5.7M
Investors
Questions about Biogenes technologies
Who invested in Biogenes technologies?
Biogenes technologies has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Biogenes technologies raised?
Biogenes technologies has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Biogenes technologies last raise money?
Biogenes technologies's most recent round on record is a Series A, in Jan 2023.
What does Biogenes technologies do?
Based in Selangor, Malaysia, and founded in 2015, Biogenes Technologies Sdn.
Where is Biogenes technologies headquartered?
Biogenes technologies is headquartered in Selangor, Malaysia.
Which VCs invest in companies like Biogenes technologies?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Biogenes technologies's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Biogenes technologies? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.